EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Multizentrische StudieRandomisierte kontrollierte StudieOpen Access

Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity

Louis J Aronne, Naveed Sattar, Deborah B Horn, Harold E Bays, Sean Wharton, Wen-Yuan Lin, Nadia N Ahmad, Shuyu Zhang, Ran Liao, Mathijs C Bunck, Irina Jouravskaya, Madhumita A Murphy und 1 weitere

JAMA · 02.01.2024 · 331 (1) · 38

DOI: 10.1001/jama.2023.24945 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift JAMA, erschienen am 02.01.2024. Verfasst von Louis J Aronne und 12 weiteren Autor:innen. Beteiligte Einrichtung: Comprehensive Weight Control Center, Division of Endocrinology, Diabetes, and Metabolism, Weill Cornell Medicine, New York, New York. Hauptthemen laut MEDLINE: Obesity, Weight Loss, Anti-Obesity Agents. Die Arbeit wurde bisher 888-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCATS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance The effect of continued treatment with tirzepatide on maintaining initial weight reduction is unknown.

Objective

To assess the effect of tirzepatide, with diet and physical activity, on the maintenance of weight reduction. Design, Setting, and Participants This phase 3, randomized withdrawal clinical trial conducted at 70 sites in 4 countries with a 36-week, open-label tirzepatide lead-in period followed by a 52-week, double-blind, placebo-controlled period included adults with a body mass index greater than or equal to 30 or greater than or equal to 27 and a weight-related complication, excluding diabetes.

Interventions

Participants (n = 783) enrolled in an open-label lead-in period received once-weekly subcutaneous maximum tolerated dose (10 or 15 mg) of tirzepatide for 36 weeks. At week 36, a total of 670 participants were randomized (1:1) to continue receiving tirzepatide (n = 335) or switch to placebo (n = 335) for 52 weeks. Main Outcomes and Measures The primary end point was the mean percent change in weight from week 36 (randomization) to week 88. Key secondary end points included the proportion of participants at week 88 who maintained at least 80% of the weight loss during the lead-in period.

Results

Participants (n = 670; mean age, 48 years; 473 [71%] women; mean weight, 107.3 kg) who completed the 36-week lead-in period experienced a mean weight reduction of 20.9%. The mean percent weight change from week 36 to week 88 was −5.5% with tirzepatide vs 14.0% with placebo (difference, −19.4% [95% CI, −21.2% to −17.7%]; P < .001). Overall, 300 participants (89.5%) receiving tirzepatide at 88 weeks maintained at least 80% of the weight loss during the lead-in period compared with 16.6% receiving placebo ( P < .001). The overall mean weight reduction from week 0 to 88 was 25.3% for tirzepatide and 9.9% for placebo. The most common adverse events were mostly mild to moderate gastrointestinal events, which occurred more commonly with tirzepatide vs placebo. Conclusions and Relevance In participants with obesity or overweight, withdrawing tirzepatide led to substantial regain of lost weight, whereas continued treatment maintained and augmented initial weight reduction. Trial Registration ClinicalTrials.gov Identifier: NCT04660643

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ObesityWeight LossAnti-Obesity AgentsAdultFemaleHumansMaleMiddle AgedDouble-Blind MethodGastric Inhibitory PolypeptideOverweightTreatment OutcomeGlucagon-Like Peptide-2 ReceptorIncretinsMaintenance ChemotherapyInjections, SubcutaneousWithholding TreatmentTirzepatide

Substanzen

Gastric Inhibitory PolypeptideTirzepatideGlucagon-Like Peptide-2 ReceptorIncretinsAnti-Obesity Agents

Autor:innen und Institutionen

  • Comprehensive Weight Control Center, Division of Endocrinology, Diabetes, and Metabolism, Weill Cornell Medicine, New York, New York.
  • BHF Glasgow Cardiovascular Research Centre, School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, United Kingdom.
  • University of Texas Center for Obesity Medicine and Metabolic Performance, Department of Surgery, University of Texas McGovern Medical School, Houston.
  • Louisville Metabolic and Atherosclerosis Research Center, Louisville, Kentucky.
  • McMaster University, and Wharton Weight Management Clinic, York University, Toronto, Ontario, Canada.
  • Department of Family Medicine, China Medical University Hospital, Taichung, Taiwan.

Förderung

  • NCATS NIH HHS

Zitieren

APA

Aronne, L. J., Sattar, N., Horn, D. B., Bays, H. E., Wharton, S., Lin, W. Y., Ahmad, N. N., Zhang, S., Liao, R., Bunck, M. C., Jouravskaya, I., Murphy, M. A., & SURMOUNT-4 Investigators (2024). Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity. JAMA, 331(1), 38. https://doi.org/10.1001/jama.2023.24945

Vancouver

Aronne LJ, Sattar N, Horn DB, Bays HE, Wharton S, Lin WY, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity. JAMA. 2024;331(1):38. doi:10.1001/jama.2023.24945

BibTeX
@article{Aronne2024,
  author = {Aronne, Louis J and Sattar, Naveed and Horn, Deborah B and Bays, Harold E and Wharton, Sean and Lin, Wen-Yuan and Ahmad, Nadia N and Zhang, Shuyu and Liao, Ran and Bunck, Mathijs C and Jouravskaya, Irina and Murphy, Madhumita A and SURMOUNT-4 Investigators, SURMOUNT-4 Investigators},
  title = {Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity},
  journal = {JAMA},
  year = {2024},
  volume = {331},
  number = {1},
  pages = {38},
  doi = {10.1001/jama.2023.24945}
}
Kostenlos starten →